References for: association

Full identifier: http://purl.org/np/RAlZalMpuCQZNNIcX-RTzTfH0fl-3Nb8WInVO5ZlNKV7U#association

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T11:41:19.462Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
imraldi is a tumor necrosis factor tnf blocker indicated for treatment of rheumatoid arthritis ra 1 1 juvenile idiopathic arthritis jia 1 2 psoriatic arthritis psa 1 3 ankylosing spondylitis as 1 4 adult crohn s disease cd 1 5 ulcerative colitis uc 1 6 plaque psoriasis ps 1 7 imraldi is indicated for reducing signs and symptoms inducing major clinical response inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis imraldi can be used alone or in combination with methotrexate or other non biologic disease modifying anti rheumatic drugs dmards imraldi is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients from 4 to 17 years of age and 3 kg 66 lbs imraldi can be used alone or in combination with methotrexate imraldi is indicated for reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in adult patients with active psoriatic arthritis imraldi can be used alone or in combination with non biologic dmards imraldi is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis imraldi is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn s disease who have had an inadequate response to conventional therapy imraldi is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab imraldi is indicated for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids azathioprine or 6 mercaptopurine 6 mp the effectiveness of adalimumab has not been established in patients who have lost response to or were intolerant to tnf blockers see clinical studies 14 7 imraldi is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate imraldi should only be administered to patients who will be closely monitored and have regular follow up visits with a physician see boxed warning 5
Leoni Bücken
2021-06-12T11:41:19.462Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T11:41:19.462Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T11:41:19.462Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T11:41:19.462Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T11:41:19.462Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T11:41:19.462Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T11:41:19.462Z